Showing 4441-4450 of 8631 results for "".
- Cutera's AviClear Now Broadly Available to US Physicians and Practitionershttps://practicaldermatology.com/news/cuteras-aviclear-now-broadly-available-to-us-physicians-and-practitioners/2461416/Cutera, Inc.’s AviClear is now broadly available to physicians and practitioners treating patients throughout North America. AviClear is the first and only energy device to be both U.S. Food and Drug Administration cleared and Health Canada approved for
- Updated: USPS Task Force Says More Research Needed to Recommend Screening Adolescents and Adults without Skin Cancer Symptomshttps://practicaldermatology.com/news/usps-task-force-more-research-needed-to-recommend-screening-adolescents-and-adults-without-skin-cancer-symptoms/2461415/More research is needed to recommend for or against screening adolescents and adults without skin cancer symptoms, according to the U.S. Preventive Services Task Force. The Task Force determined that there is not enough evidence to recommend for or against screening people without
- It's Time to Celebrate Allergan Aesthetics' Fourth Annual BOTOX Cosmetic Dayhttps://practicaldermatology.com/news/its-time-to-celebrate-allergan-aesthetics-fourth-annual-botox-cosmetic-day/2461413/Allergan Aesthetics is inviting people across the country to take a "Moment for You" on Wednesday, November 16 and celebrate the biggest event of the year for Botox Cosmetic. For this year's celebration, BOTOX® Cosmetic is sharing two exclusive offers availab
- Almirall’s New Psoriasis Campaign Sheds Light on How the Disease Affects Mental Health and Wellbeinghttps://practicaldermatology.com/news/almiralls-new-psoriasis-campaign-sheds-light-on-how-the-disease-affects-mental-health-and-wellbeing/2461407/Almirall and the International Federation of Psoriasis Association are launching the second edition of the "Shedding Light on Psoriasis" campaign for World Psoriasis Day 2022. Shedding Light on Psoriasis 
- Kintor Pharma Completes Enrollment and Dosing in Phase I Clinical Trial of AGA, Acne Drughttps://practicaldermatology.com/news/kintor-pharma-completes-enrollment-and-dosing-in-phase-i-clinical-trial-of-aga-acne-drug/2461404/Kintor Pharmaceutical Limited has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne. Developed through Kintor Pharma's proprietary Proteolysis Targeting Chimera (PROTAC) platfo
- EltaMD Honored in Fast Company Magazine’s 2022 “Brands That Matter” Listhttps://practicaldermatology.com/news/eltamd-honored-in-fast-company-magazines-2022-brands-that-matter-list/2461402/EltaMD has been named to Fast Company’s “Brands that Matter” list for its memorable campaign to increase awareness of skin cancer and how to prevent it. The list honors companies and nonprofits that have had an undeniable impact on business and culture. Skin
- One Year Data: Cutera’s AviClear Continues to Improve Acnehttps://practicaldermatology.com/news/one-year-data-cuteras-aviclear-comtinues-to-improves-acne/2461400/Cutera, Inc.’s AviClear improves acne in 92 percent of patients at one year, according to research presented at the Annual Fall Clinical Dermatology Conference in Las Vegas. Current clinical studies show that after three 30-minute treatment sessions, 90 percent of patients had a v
- Hair Straightening Chemicals Associated with Higher Uterine Cancer Riskhttps://practicaldermatology.com/news/hair-straightening-chemicals-associated-with-higher-uterine-cancer-risk/2461397/Chemical hair straighteners may be contributing to a rise in aggressive uterine cancers a new study in the Journal of the National Cancer Institute suggests. The
- Extreme Weather and Skin Disease: What’s the Connection?https://practicaldermatology.com/news/extreme-weather-and-skin-disease-whats-the-connection/2461395/As floods, wildfires, and extreme heat events increase in frequency and severity, they pose a significant threat to global dermatological health, as many skin diseases are climate sensitive, according to The Journal of Climate Change and Health. “We wanted to provide dermatol
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s